Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  CVS Health Corporation    CVS

CVS HEALTH CORPORATION (CVS)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets

CVS Caremark Corporation : U.S. asks CVS about its prescription discount plan

share with twitter share with LinkedIn share with facebook
share via e-mail
0
02/17/2012 | 10:28pm CEST

(Reuters) - CVS Caremark Corp said it received requests for information about a prescription drug discount program it runs for uninsured or under-insured individuals from both the U.S. government and the Texas Attorney General.

In January, CVS received a subpoena from the U.S. Office of Inspector General requesting information about the company's Health Savings Pass program, CVS said in its 10k filing on Friday.

The company, which runs the CVS pharmacy chain and the CVS Caremark pharmacy benefits management service, said the request was connected to an investigation of possible false or otherwise improper claims for payment involving Health & Human Services programs.

In February, CVS received a civil investigative demand from Texas' Office of the Attorney General. That office requested a copy of information from the OIG subpoena and other information related to prescription drug claims submitted by CVS pharmacies to Texas Medicaid for reimbursement, the company said.

CVS said it would respond to the requests for information and cooperate with both investigations.

CVS markets its Health Savings Pass, which has a $15 annual fee, to people who do not have prescription drug coverage and to those who have limited coverage.

The Health Savings Pass lets patients fill 90-day prescriptions for 400 generic drugs for $11.99. Participants also get discounts such as 10 percent off visits at the CVS in-store health clinic, MinuteClinic and 10 percent off an annual flu shot.

The announcement comes about a month after CVS agreed to pay $5 million to settle charges of inaccurate pricing of some drugs for the elderly and disabled, ending a wide-ranging, multi-year probe into its business practices.

Shares of CVS closed down 28 cents at $44.27, after reaching a new high of $45 earlier in the day.

(Reporting by Jessica Wohl in Chicago; Editing by Richard Chang)

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on CVS HEALTH CORPORATION
05/18CVS HEALTH : AG Curtis Hill Lauds CVS Officials for Drug-Disposal Plans
AQ
05/17CVS HEALTH : AG Curtis Hill to Join CVS Officials to Discuss Drug Disposal
AQ
05/14U.S. to consider expanding Medicare drug price negotiation
RE
05/14CVS HEALTH : Thinking about buying stock in Apple, CVS Health Corp, Facebook, Sy..
PR
05/12CVS HEALTH : installs medication disposal units across the state
AQ
05/12Trump assails high drug prices, avoids direct hit on industry
RE
05/11Trump's Plan to Cut Drug Prices Leaves Industry Relieved
DJ
05/11CVS HEALTH : Foundation gives $20K to Free Clinic of Meridian
AQ
05/11CVS HEALTH : Statement on Trump Administration Initiative to Reduce Drug Costs
PR
05/09CVS HEALTH : American Lung Association's LUNG FORCE Heroes Share Their Stories t..
AQ
More news
News from SeekingAlpha
05/2110 Dividend Growth Stocks For May 2018 
05/19Consider Selling When Your Stock Does This 
05/18A 'VALUE-ABLE' EDUCATION : My Journey In Value Investing 
05/18AMAZON GO : Stores Worth Less Than Tech 
05/15Biotechs Emerge Unscathed And Ready To Go! 
Financials ($)
Sales 2018 189 B
EBIT 2018 9 961 M
Net income 2018 5 331 M
Debt 2018 19 170 M
Yield 2018 3,05%
P/E ratio 2018 12,82
P/E ratio 2019 10,00
EV / Sales 2018 0,45x
EV / Sales 2019 0,42x
Capitalization 66 001 M
Chart CVS HEALTH CORPORATION
Duration : Period :
CVS Health Corporation Technical Analysis Chart | CVS | US1266501006 | 4-Traders
Technical analysis trends CVS HEALTH CORPORATION
Short TermMid-TermLong Term
TrendsNeutralNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 22
Average target price 86,4 $
Spread / Average Target 32%
EPS Revisions
Managers
NameTitle
Larry J. Merlo President, CEO & Non-Independent Director
David Wyatt Dorman Chairman
Jonathan C. Roberts Chief Operating Officer & Executive Vice President
David M. Denton Chief Financial Officer & Executive Vice President
Troyen A. Brennan Chief Medical Officer & Executive Vice President
Sector and Competitors
1st jan.Capitalization (M$)
CVS HEALTH CORPORATION-9.66%66 001
WALGREENS BOOTS ALLIANCE-11.18%63 804
EXPRESS SCRIPTS HOLDING CO2.52%42 494
MCKESSON CORPORATION-6.06%30 728
AMERISOURCEBERGEN-8.15%18 633
CARDINAL HEALTH-13.29%16 783